Filing Flows › Prelude Therapeutics (PRLD) › Recalls, complaints & regulation
Prelude Therapeutics (PRLD): clinical trials
Prelude Therapeutics (PRLD) beyond its filings: 2 active clinical trials.
Prelude Therapeutics' latest quarter
Prelude Therapeutics, Q2 2026: revenue $5.7M, operating margin -270.9%, net loss $13.9M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Prelude Therapeutics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.